Leerink Partners Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390

Futu NewsDec 18 14:31 · Ratings

Sagimet Started at Outperform by Oppenheimer, MASH Drug Cited

Seeking AlphaDec 7 02:56

Madrigal Pharmaceuticals Price Target Raised to $427 From $415 at JMP Securities

Yahoo FinanceDec 6 19:46

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,135,122, According to a Recent SEC Filing

MT NewswiresDec 6 05:51

Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Path To Profitability

Simply Wall StDec 3 18:09

Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL)

TipRanksNov 28 18:01 · Ratings